LEO Pharma / Astellas Pharma merger inquiry

The CMA investigated the anticipated acquisition by LEO Pharma A/S (LEO) of the portfolio of pharmaceutical dermatological products of Astellas Pharma Inc (Astellas).

Statutory timetable

Phase 1 dates Action
5 April 2016 Decision published
11 March 2016 Decision announced
22 January 2016 Launch of merger inquiry
22 January to 5 February 2016 Invitation to comment

Phase 1

CMA clearance decision

11 March 2016: The CMA has cleared the acquisition by LEO Pharma A/S (LEO) of the portfolio of pharmaceutical dermatological products of Astellas Pharma Inc (Astellas). The full text of the decision is available below.

Launch of merger inquiry

22 January 2016: The CMA announced the launch of its merger inquiry by notice to the parties.

Invitation to comment: Now closed

22 January 2016: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

Contact

Please send written representations about any competition or public interest to:

Tobe Nwaogu
Competition and Markets Authority
Victoria House
37 Southampton Row
London
WC1B 4AD

tobe.nwaogu@cma.gsi.gov.uk

Published 22 January 2016
Last updated 5 April 2016 + show all updates
  1. Full text of the decision published.
  2. Clearance decision announced.
  3. First published.